TL;DR
Liraglutide demonstrated the ability to mitigate lipid accumulation, oxidative stress, and iron overload in HepG2 cells subjected to FFA-induced injury, suggesting a mechanistic basis for the potential protective role of liraglutide in MASLD.
Background Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease with limited pharmacological treatment options. Wogonoside (WOG), a flavonoid isolated from Scutellaria baicalensis, exhibits anti-inflammatory, antioxidant, and lipid-low...
BACKGROUND AND AIMS Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by hepatic lipid accumulation, inflammation, and oxidative injury. However, the regulatory role of integrin beta-like 1 (ITGBL1) in MASH remains unknown. METHODS ITGBL1 knockout (KO) and liver-specific overexpressing mice wer...
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing metabolic disorder with no FDA-approved treatment. Pachymic acid (PA; synonym: 3-O-acetyltumulosic acid), a lanostane-type triterpenoid, shows potential for treating MASLD. However, its mechanisms remain underexplored. Obje...
BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by abnormalities in secreted protein biosynthesis. A comprehensive understanding of secreted proteins could lead to improved diagnostics and therapies for MASLD. This study investigates the therapeutic potential of lipocalin 13...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
